ARTICLE | Company News
Novartis gets North American rights to NN622
July 19, 2001 7:00 AM UTC
Novartis (NVS; SWX:NOVN) received exclusive North American marketing rights to NN622, a peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist insulin sensitizer, from Novo Nordisk ...